This is mainly attributed to the successfulclinical translation of both diagnostic and therapeutic radioligandstargeting the somatostatin receptor subtype 2 (SST2) totreat neuroendocrine tumors and prostate-specific membrane antigen(PSMA) to treat prostate cancer. Here, FOLH1 is linked to neuroendocrine neoplasm.